Pharmaceutical Directory – A Complete A to Z Directory for Indian Pharmaceutical & Biopharmaceutical Industry. PharmaExpress directory is FREE to add and curated by PharmaExpress – Directory Services Team.
Headquartered in Mumbai, India, Lupin Limited today is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world.
Dr. Desh Bandhu Gupta’s vision and dream to fight life threatening infectious diseases and to manufacture drugs of the highest social priority led to the formation of Lupin in the year 1968. His Vision, his inimitable commitment and verve have steered Lupin to achieving the distinction of becoming one of the fastest growing Generic pharmaceutical companies globally.
Lupin first gained recognition when it became one of the world’s largest manufacturers of Tuberculosis drugs. The Company today has significant market share in key markets in the Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins segments. The Company’s R&D endeavours have resulted in significant progress in its NCE program. The Company’s foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals. Lupin’s world class manufacturing facilities, spread across India and Japan, have played a critical role in enabling the companies realize its global aspirations. Benchmarked to International standards, these facilities are approved by international regulatory agencies like US FDA, UK MHRA, Japan’s MHLW, TGA Australia, WHO, and the MCC South Africa.
Our Drugs and products reach over 70 countries in the world. Today, Lupin has emerged as the 5th largest and the fastest growing Top 5 company in the U.S (by prescriptions), the only Asian company to achieve that distinction. The company is also the fastest growing, top 5 pharmaceutical players in India (ORG IMS) and the fastest growing top 10 Generic players in Japan and South Africa. (IMS), Today, Lupin also has the unique distinction of being the fastest growing top 10 Generics players in the two largest pharmaceutical markets of the world – The U.S (ranked 5th by prescriptions & growing at 52 %) and Japan (ranked 7th and growing at 23%). Lupin’s Consolidated Revenues and Profit after Tax were Rs. 57,068 million and Rs. 8,626 million for FY 2010-11.
Going forward, our research backbone, best-in-class class manufacturing capabilities, marketing and servicing depth globally will stand us in good stead. The company will continue to focus on identifying and developing niche segments, a differentiated product portfolio in all its chosen markets backed up by strategic partnerships and in-licensing, and investment in new areas such as biosimilars – well on-course to becoming a global pharmaceutical powerhouse.
The Lupin Story
The company was named after the Lupin flower because of the inherent qualities of the flower and what it personifies and stands for. The Lupin flower is known to nourish the land, the very soil it grows in. The Lupin flower is also known to be tolerant of infertile soils and capable of pioneering change in barren and poor climes. The Lupin flower and bean pods have also long been used as food and sources of nourishment, thus protecting and nurturing life.
Embedded inLupin was a formula for growth. Forty-four years on, what has stayed with us is that same entrepreneurial spirit, culture of creativity and innovation and pride in belonging to an industry that makes a difference in the lives of people.
We are today a fully integrated pharmaceutical company with an unrivaled position in the US, India and Japan. This position is built on a backbone of cutting-edge research, world-class manufacturing facilities and a truly global supply chain. With the building blocks in place, the future looks brighter than its ever been. We are Built to Grow.
Built to Grow
Lupin is poised and ready for its future. We have all the elements in place to play a major role in the global pharmaceutical landscape and to continue our mission of delivering consistent high growth in revenues, margins and returns for our Company and its stakeholders.
Our culture of growth is built upon trust and transparency in all our dealings and in all our relationships. Be those relationships with our customers, our investor communities, our people or society at large. We are proud to be part of an industry that can make a real difference to people’s lives. We now stand ready to grasp opportunities emerging in a new world. Global economies are going though challenging times. Over our 44-year history we have been through such cycles before and we have learnt that a firm foundation, a passionate growth ethic embedded in a sound business strategy, underpinned by a strong balance sheet are the essentials for success.
A thirst for growth has been the common thread binding us with our heritage. But for us, growth is not just the numbers; it is our part in enhancing the knowledge, experience and talent of our people that we value and nurture. We are an agile organization, working as a global team, creating and unlocking value. Lupin is Built as One, Built to Enrich.
Transnational Pharmaceutical Company”
“Our aspiration is to become a multi-billion dollar transnational company and be counted amongst the top generic pharmaceutical companies in the world. Going forward, we have to consistently set ourselves standards and benchmarks that will be world-class but uniquely Lupin.”
“Today, Lupin is at a very interesting point of its evolution, well on course on its intended journey to emerge as a global generics powerhouse – a point in time where I find not only a new level of energy and excitement brewing within Lupin’s rank and file, but most importantly, a keen sense of pointed urgency to achieve and excel.”
My Dear Shareowners
When I started Lupin over 40 years ago, the dream was simple – to provide as many people as possible with affordable medicines that would address the most prevalent diseases of the highest social priority, such as tuberculosis. I discovered that by working hard on a noble ambition, growth and success followed.
Embedded in Lupin is a formula for this growth. Growth fuelled by a boundless vision, the determination to succeed and reach for our dreams. These fundamental philosophies are what drive Lupin – creativity, performance and innovation.
Lupin has delivered the highest growth performance consistently over the past ten years. We expect the future to be no different and we continue to invest in new therapy areas, reach out to new territories and dive deeper into our existing markets. As we have grown as a company, we realized that our ambitions were bigger than generic products alone and that we had the means to go up the value chain into specialty products and proprietary research and development. That is the journey we are on today – to become a global specialty pharmaceutical company offering a wide portfolio of generic and proprietary products.
As always, it is a pleasure for me to address you and to share our results for the previous year. We have carefully put together all the pieces of our story, to be counted amongst the leading pharmaceutical companies in the world. Lupin is Built to Grow.
With Best Wishes,
Dr. Desh Bandhu Gupta
Founder and Chairman
|2012||Lupin bags “Niryat Shree” Gold Trophy for ‘outstanding export performance’ in the category of chemicals, drugs, pharma and allied products, during the year 2009-2010, by FIEO (Federation of Indian Export Organisations).|
|Lupin has been recognised as “India’s Best Company to Work For” in the Biotech and Pharmaceutical sector, in the survey conducted by the Great Place to Work Institute ® and the Economic Times.|
|Dr Desh Bandhu Gupta (Founder & Chairman) has won the ‘Ernst & Young Entrepreneur of the Year 2011′ Award in the Life sciences and Healthcare sector.|
|Lupin has won the NDTV Business Leadership Awards, 2011: Indian Pharmaceutical Company of the Year|
|Mrs Vinita Gupta won the Business Today ’30 Most Powerful Women in Business’ award.|
|Mr Ramesh Swaminathan won the Business Today Yes Bank ‘Best CFO Award – Best Leverage Management – Large Companies’|
|2011||Healthcare Distribution Management Association (HDMA) Honors Lupin with DIANA Award for Best Overall Generic Product Manufacturer|
|Top Indian Pharma company under the ‘Pharmaceuticals’ sector for the Dun & Bradstreet – Rolta Corporate Awards 2010.|
|Lupin ranked amongst India’s Top 3 ‘Best Companies to Work For’ in Healthcare and Pharma Sector.|
|Hall of Fame Award by Chemtech Foundation (Leadership and Excellence Awards)|
|IMM (Institute of Marketing and Management) Award for Excellence as Top Organisation.|
|Lupin ranked 2nd amongst India’s “Best Companies to Work for” in the Biotechnology and Pharmaceutical Sector.|
|2010||Indian Pharmaceutical Company of the Year 2010″ by Frost & Sullivan India Excellence in Healthcare Awards 2010.|
|Best Drug Development Company, Asia’ by The New Economy Pharmaceutical & Healthcare Awards 2010|
|Lupin wins ‘The Most Promising Entrant into the Big League’ by CNBC India Business Leader Awards 2010|
|2009||International Excellence Award by Institute of Economic Studies.|
|Outstanding Export Performance Award by Pharmexcil (Pharmaceuticals Export Promotion Council of India)|
History & Milestones
Send Message to listing owner